| 000 | 01612 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516172035.0 | ||
| 264 | 0 | _c20140717 | |
| 008 | 201407s 0 0 eng d | ||
| 022 | _a1536-3694 | ||
| 024 | 7 |
_a10.1097/FTD.0b013e318297b6b0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHelmy, Sally A | |
| 245 | 0 | 0 |
_aSimultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers. _h[electronic resource] |
| 260 |
_bTherapeutic drug monitoring _cDec 2013 |
||
| 300 |
_a770-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Validation Study | ||
| 650 | 0 | 4 |
_aAcetamides _xblood |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Infective Agents _xblood |
| 650 | 0 | 4 |
_aAza Compounds _xblood |
| 650 | 0 | 4 |
_aChromatography, High Pressure Liquid _xmethods |
| 650 | 0 | 4 |
_aDrug Monitoring _xmethods |
| 650 | 0 | 4 |
_aFluoroquinolones _xblood |
| 650 | 0 | 4 | _aGatifloxacin |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevofloxacin _xblood |
| 650 | 0 | 4 | _aLimit of Detection |
| 650 | 0 | 4 | _aLinezolid |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMoxifloxacin |
| 650 | 0 | 4 |
_aNorfloxacin _xblood |
| 650 | 0 | 4 |
_aOxazolidinones _xblood |
| 650 | 0 | 4 |
_aQuinolines _xblood |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 |
_aTinidazole _xblood |
| 650 | 0 | 4 | _aYoung Adult |
| 773 | 0 |
_tTherapeutic drug monitoring _gvol. 35 _gno. 6 _gp. 770-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/FTD.0b013e318297b6b0 _zAvailable from publisher's website |
| 999 |
_c23112653 _d23112653 |
||